729 related articles for article (PubMed ID: 23621720)
21. Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.
Park SY; Oh IH; Lee HJ; Ihm CG; Son JS; Lee MS; Kim MN
Antimicrob Agents Chemother; 2013 Nov; 57(11):5536-42. PubMed ID: 23979741
[TBL] [Abstract][Full Text] [Related]
22. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
[TBL] [Abstract][Full Text] [Related]
23. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
[TBL] [Abstract][Full Text] [Related]
24. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method.
Wang JL; Wang JT; Sheng WH; Chen YC; Chang SC
BMC Infect Dis; 2010 Jun; 10():159. PubMed ID: 20529302
[TBL] [Abstract][Full Text] [Related]
25. Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: a propensity-matched analysis.
Yoon YK; Park DW; Sohn JW; Kim HY; Kim YS; Lee CS; Lee MS; Ryu SY; Jang HC; Choi YJ; Kang CI; Choi HJ; Lee SS; Kim SW; Kim SI; Kim ES; Kim JY; Yang KS; Peck KR; Kim MJ
BMC Infect Dis; 2016 Jul; 16():331. PubMed ID: 27418274
[TBL] [Abstract][Full Text] [Related]
26. Impact of Vancomycin MIC on Treatment Outcomes in Invasive Staphylococcus aureus Infections.
Song KH; Kim M; Kim CJ; Cho JE; Choi YJ; Park JS; Ahn S; Jang HC; Park KH; Jung SI; Yoon N; Kim DM; Hwang JH; Lee CS; Lee JH; Kwak YG; Kim ES; Park SY; Park Y; Lee KS; Lee YS; Kim HB
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956430
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
[TBL] [Abstract][Full Text] [Related]
28. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
[TBL] [Abstract][Full Text] [Related]
29. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.
Maclayton DO; Suda KJ; Coval KA; York CB; Garey KW
Clin Ther; 2006 Aug; 28(8):1208-1216. PubMed ID: 16982298
[TBL] [Abstract][Full Text] [Related]
30. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
[TBL] [Abstract][Full Text] [Related]
31. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia?
de Sanctis JT; Swami A; Sawarynski K; Gerasymchuk L; Powell K; Robinson-Dunn B; Carpenter CF; Sims MD
Diagn Mol Pathol; 2011 Sep; 20(3):184-8. PubMed ID: 21817905
[TBL] [Abstract][Full Text] [Related]
32. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic changes of methicillin-resistant Staphylococcus aureus during vancomycin therapy for persistent bacteraemia and related clinical outcome.
Kim T; Kim ES; Park SY; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Chong YP; Kim YS
Eur J Clin Microbiol Infect Dis; 2017 Aug; 36(8):1473-1481. PubMed ID: 28337607
[TBL] [Abstract][Full Text] [Related]
34. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
Rojas L; Bunsow E; Muñoz P; Cercenado E; Rodríguez-Créixems M; Bouza E
J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382
[TBL] [Abstract][Full Text] [Related]
35. The Influence of the Route of Antibiotic Administration, Methicillin Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection.
McNeil JC; Kaplan SL; Vallejo JG
Pediatr Infect Dis J; 2017 Jun; 36(6):572-577. PubMed ID: 28027279
[TBL] [Abstract][Full Text] [Related]
36. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
[TBL] [Abstract][Full Text] [Related]
37. Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia.
Kaku N; Yanagihara K; Morinaga Y; Yamada K; Harada Y; Migiyama Y; Nagaoka K; Matsuda J; Uno N; Hasegawa H; Miyazaki T; Izumikawa K; Kakeya H; Yamamoto Y; Kohno S
J Infect Chemother; 2014 Jun; 20(6):350-5. PubMed ID: 24731430
[TBL] [Abstract][Full Text] [Related]
38. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
39. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.
Yoon YK; Kim JY; Park DW; Sohn JW; Kim MJ
J Antimicrob Chemother; 2010 May; 65(5):1015-8. PubMed ID: 20200036
[TBL] [Abstract][Full Text] [Related]
40. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
